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determining the characteristics and prognosis of patients treated by hypothermia
in a Cardiac Intensive Care Unit of a French University Hospital for an OHCA.
Methods: We analyzed data of patients admitted during the 3 last years
(2008-10) for management of an OHCA related to a ventricular arrhythmia,
by therapeutic hypothermia. Main characteristics were compared according to
the intra hospital outcome.
Results: During the inclusion time, 53 patients (mean age: 58±15; male:
48 (90%)) were enrolled, included 18 STEMI (34%). Mean resuscitation
delays were: “no flow” 4.4±6, “low flow” 23.2±16 minutes. Comparison of
main data according to the intra hospital outcome (“Good outcome” group are
patient discharged with good cerebral performance or moderate cerebral dis-
ability) is presented in table 1.
Conclusion: prognosis of OHCA is still poor. Factors associated with good
prognosis are: male gender, short delays of resuscitation (“no flow” and “low
flow”), low lactate blood, coronary artery disease on the admission angio-
graphy and angioplasty.
Table – Comparison of main data according to the intra hospital outcome.
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Prasugrel a new thienopyridine inhibits adenosine diphosphate induced
platelet aggregation more rapidly, more consistently, and to a greater extent
than do standard and higher doses of clopidogrel.
The aim of this study was to compare the effect of pre-hospital treatment
with prasugrel and clopidogrel on the TIMI flow in patients admitted in cath
lab with acute STEMI in 2010. The primary efficacy endpoint was the supe-
riority of TIMI flow in patients pretreated with prasugrel and reduction of use
of Glycoprotein IIb/IIIa inhibitors in primary PCI. The key safety endpoint
was tolerance of prasugrel and bleeding.
The primary efficacy endpoint occurred in 41% of patients receiving pra-
sugrel and 33% of patients receiving clopidogrel (p=0.251).The subgroup (ST
elevation within 6h ) had the maximal profit of TIMI FLOW with 44.1% in
the prasugrel arm compared with 27.4% in the clopidogrel arm (p=0.088). No
difference in the term of reduction of Glycoprotein IIB/IIIa inhibitors use in
primary PCI (p=0.352). The patients receiving prasugrel had a very good tol-
erance without elevation in rates of major bleeding.
In conclusion, there was no significant difference in term of TIMI Flow
and use of Inhibitors of Glycoprotein IIb/IIIa in primary PCI between the pra-
sugrel and clopidogrel groups. The patients presenting within 6h of ST seg-
ment elevation had a better TIMI flow if pretreated with prasugrel (P=0.088)
with 16.67% gain in good TIMI flow in favor of prasugrel. More studies are
needed.
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Background: New troponin assays achieve early high sensitivity. A normal
single high sensitive (HS) troponin at time of admission might rule out acute
coronary syndrome.
Methods: Patients with acute chest pain and low to intermediate likelihood
of coronary artery disease were referred to a dedicated protocol in our chest
pain unit. Patients with normal initial EKG and no noticeable alternative cause
than ACS were evaluated by a single Troponin I test (Vitros I ES assay,
threshold 0.012 ng/mL, 99th percentile 0.034 ng/mL) at time of admission. All
patients with normal HS troponin were referred to coronary computed tomog-
raphy (CCT) angiography within 3 hours (General Electric 64-detectors Scan).
Patients with suspected coronary obstruction by CCT were admitted and HS
troponin aditionnally tested between 6 and 24 hours.
Results: Sixty eight patients (54+/–13 years) referred to our chest pain unit
showed normal initial Troponin and EKG. Pre test- likelihood for coronary
artery disease was 58%+/–24%. CCT was performed and coronary angiog-
raphy reconstruction was evaluable in all patients. CCT showed significant
obstruction (>50% stenosis) in 13 patients (19%). Invasive coronary angiog-
raphy was performed and confirmed significant obstrution in 8 patients (12%).
Multivessel disease was observed in 6 and TIMI flow was <3 in 3. Serial
troponin sampling showed HS troponin elevation in only one patient.
Conclusions: In low risk patients with acute chest pain, a normal single HS
troponin sample does not rule out acute coronary syndrome. Increasing patient
detection is more efficiently performed by Coronary CT at time of admission
than HS troponin serial sampling.
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Two large studies recently related that the combination of copeptin and
troponin had a remarkable negative predictive value to rule out myocardial
infarction (MI).
Good 
outcome
Group
n=22
Poor 
outcome
Group
n=31
p
Clinical Male 22 (100) 26 (83) 0.04
Age 55 ±13 60±16 0.27
Diabetes mellitus 3 (13) 4 (13) 0.93
Current smoker 6 (27) 9 (29) 0.88
Known cardiopathy 9 (41) 21 (67) 0.052
Anamnesis
of the cardiac 
arrest and 
management
Time of occurring
(6 am-6 pm)
16 (72) 22 (71) 0.28
“No flow” delay 
(minutes)
2 ±3 5 ±6 0.039
“Low flow” delay 
(minutes)
15 ±14 29 ±16 0.003
STEMI 10 (45) 9 (29) 0.21
Coronary artery 
disease on the admission 
angiography
18 (81) 16 (51) 0.02
Angioplasty 13 (59) 4 (13) <0.001
Delay between OHCA 
and beginning 
of hypothermia (minutes)
181 ±78 233 ±113 0.08
Biomarkers
at the admission
Troponin (ng/ml) 12.7±30 3.1 ±4 0.09
Lactate blood (mmol/l) 2.4 ±1 4.0 ±2 0.009
pH 7.33 ±0.1 7.29 ±0.1 0.18
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